Superpower Health Review: What the Prescribing Data and Outcomes Signals Actually Tell Women

What Is Superpower and How Does Its Model Work?

Superpower positions itself as a preventive health subscription that combines broad laboratory testing with clinician-reviewed prescriptions, targeting people who want to optimize health before symptoms appear. The pitch is appealing: one monthly fee, a deep lab panel, and a clinician who can prescribe based on what the numbers show.

The model is not new. Direct-to-consumer preventive lab platforms have grown sharply since 2020, partly because primary care visit times average only 18 minutes, leaving little room for the kind of biomarker-level conversation Superpower promises.

How the Subscription Is Structured

Members pay a recurring fee, submit blood draws at partner labs, and receive a dashboard with results plus a telehealth consult. Prescriptions, if issued, flow through affiliated pharmacies. The company markets this as "owning your biology."

Where Women Fit In (and Where They Don't)

Here is the practical problem. The platform's default lab panel was designed with a general adult in mind, which in most tech-health spaces defaults toward male physiology. Women asking about progesterone, AMH, estradiol, DHEA-S, or thyroid antibodies typically find those markers listed as optional upgrades rather than core panel items. That framing matters because conditions like PCOS affect 6 to 13 percent of reproductive-age women and are frequently identified through exactly those hormone markers that Superpower treats as extras.

Is Superpower Legit? Regulatory and Accreditation Status

Legitimacy for a telehealth prescribing platform rests on several pillars: state medical board compliance, pharmacy licensing, LegitScript certification, and BBB standing. Superpower's current status on each deserves a straight answer.

LegitScript and FDA-Adjacent Verification

LegitScript is the primary third-party certification body that the FDA and major payment processors rely on when evaluating online pharmacies and telehealth prescribers. As of the date this article was reviewed, Superpower does not appear on LegitScript's verified telehealth merchant list. That absence does not automatically mean the platform is operating illegally, but it does mean consumers cannot use LegitScript verification as a trust signal here.

The FDA's own guidance on buying medicine online identifies LegitScript certification and a verifiable U.S.-licensed pharmacist as baseline markers of legitimacy. Women obtaining prescriptions through Superpower should independently confirm the dispensing pharmacy holds a valid state license through the NABP database.

BBB Accreditation and Consumer Complaints

Superpower is not listed as BBB-accredited. The BBB complaint database shows a small number of consumer filings, predominantly related to billing disputes and difficulty canceling subscriptions. Complaint volume is low enough that it does not constitute a pattern of clinical harm, but the billing friction is a documented consumer experience worth knowing before you enter your credit card.

State Medical Board Compliance

Telehealth prescribing must comply with the laws of the state where the patient is located at the time of service. Superpower uses affiliated clinicians licensed across multiple states, which is common practice. The company does not publish a list of which states it serves or which state boards its clinicians are licensed under. Women should ask this question directly before their first consult, particularly if they are in states with stricter telehealth prescribing rules such as Texas or Florida.

Prescribing Data: What Signals Exist and What Is Missing

No peer-reviewed publication has examined Superpower's prescribing patterns specifically. What follows is a framework for evaluating any direct-to-consumer prescribing platform when independent outcomes data is absent, because that framework itself is information you will not find assembled this way elsewhere.

The Three Data Layers Any Telehealth Platform Should Be Able to Show

Layer 1: Prescribing volume and breadth. What drugs are being prescribed, at what doses, and for what indications? A platform prescribing testosterone to women, for example, should be able to tell you what percentage of female members receive it, at what dose range, and whether prescribing follows the Endocrine Society clinical practice guideline on androgen therapy in women.

Layer 2: Follow-up and monitoring rates. Responsible prescribing of hormones, thyroid medications, or metabolic agents requires interval labs. Does the platform track whether members actually complete follow-up panels? ACOG guidance on complex prescribing consistently emphasizes structured monitoring, not one-time lab snapshots.

Layer 3: Adverse event and discontinuation reporting. How many members stopped a prescribed medication due to side effects? How many reported adverse events? Reputable platforms surface this. Superpower does not publish this data publicly.

Women evaluating Superpower should ask the platform directly for all three layers. If they are not provided, that itself is an outcomes signal.

What the Absence of Published Data Actually Means

The absence of peer-reviewed outcomes data from a commercial platform is not unusual. Most telehealth startups do not publish clinical research. The concern specific to Superpower is the mismatch between its claims, framing itself as a science-forward, data-driven health company, and the absence of any data shared with the public or submitted to a registry. ClinicalTrials.gov shows no registered trials affiliated with Superpower as of mid-2025.

That does not mean harm is occurring. It means you are being asked to trust the platform on the basis of marketing rather than evidence.

Women's Physiology, Hormonal Status, and the Drugs Superpower Prescribes

Superpower's prescriptions cluster around what the longevity and optimization space calls "performance" biomarkers: testosterone, DHEA, thyroid (including T3/T4 combinations), metformin for metabolic optimization, and various peptides. Each of these intersects with female physiology in ways that require sex-specific clinical judgment.

Testosterone in Women

Testosterone is not a male hormone. Women produce it in the ovaries and adrenal glands, and levels decline across the reproductive years, dropping roughly 50 percent between the ages of 20 and 45. Low testosterone in women can contribute to low libido, fatigue, and reduced muscle mass, and The Menopause Society acknowledges a role for testosterone therapy in postmenopausal women with hypoactive sexual desire disorder (HSDD).

The clinical problem with a general optimization platform prescribing testosterone to women is dose specificity. Women require doses roughly one-tenth of those used in men. Off-label female testosterone therapy at doses calibrated for male physiology causes virilization: acne, clitoral enlargement, voice changes, and cycle disruption. A platform that is not asking detailed menstrual cycle questions and tracking cycle effects is missing information that a women's-health clinician would consider standard.

For women who are premenopausal and trying to conceive, supraphysiologic testosterone is not appropriate. The ASRM does not endorse testosterone supplementation as a fertility intervention in women outside of specific IVF protocols. Any platform prescribing testosterone to a woman of reproductive age without a documented discussion of contraception and fertility intentions is operating below the standard of care.

DHEA

DHEA is a steroid precursor that converts to both testosterone and estrogen in peripheral tissues. FDA approval of intravaginal DHEA (prasterone) is limited to dyspareunia in postmenopausal women, but oral DHEA is sold as a supplement and sometimes prescribed off-label for premenopausal women. Systemic effects in premenopausal women are poorly characterized. The evidence base for oral DHEA supplementation as a general "optimization" tool in women is weak, and the Endocrine Society does not recommend it for this purpose.

Thyroid Combinations (T3/T4)

Some optimization platforms prescribe desiccated thyroid or T3/T4 combinations to people with normal or low-normal TSH, framing this as optimizing rather than replacing thyroid function. ATA guidelines do not support treating euthyroid individuals with thyroid hormone, and doing so in women carries specific risks. Thyroid hormone affects bone mineral density, and women already carry higher lifetime risk for osteoporosis. Overtreatment also disrupts menstrual regularity and can impair fertility. Women in perimenopause, where TSH naturally fluctuates, are particularly vulnerable to overinterpretation of borderline labs.

Metformin for Metabolic Optimization

Metformin use in non-diabetic women for longevity or weight management is an active area of research, but not yet guideline-supported outside of PCOS management. The ongoing TAME trial (NCT03325764) is examining metformin for aging, but results are not yet available. In women with PCOS, metformin is supported by evidence and can improve menstrual regularity and insulin sensitivity. Outside of that context, prescribing it to healthy, non-diabetic women remains off-label and should involve a documented informed consent discussion about gastrointestinal side effects and the B12 depletion that occurs with long-term use.

Pregnancy, Lactation, and Contraception: What Superpower Must Screen For

Several drugs in Superpower's prescribing repertoire carry pregnancy risks that demand explicit screening. This is not optional clinical practice. It is a patient-safety floor.

Testosterone: Classified as FDA Pregnancy Category X. Exposure during pregnancy causes virilization of female fetuses. Women of reproductive age receiving testosterone must use reliable contraception. There is no safe dose in pregnancy.

DHEA (systemic oral): Not formally categorized due to supplement status, but as an androgen precursor, the teratogenic risk profile mirrors testosterone. Avoid in pregnancy and in anyone not using effective contraception.

Metformin: FDA Pregnancy Category B, with the largest human evidence base in women with PCOS and gestational diabetes. Metformin crosses the placenta. Current ACOG guidance permits metformin in GDM when insulin is declined, but does not endorse it as a first-line optimization agent in non-diabetic pregnant women.

Thyroid hormone (T3-containing preparations): T3 crosses the placenta in limited amounts, but suppressed maternal TSH during pregnancy is associated with adverse fetal outcomes. ATA pregnancy guidelines state clearly that TSH should be maintained within trimester-specific reference ranges, not suppressed.

Lactation: Testosterone and DHEA transfer into breast milk. No safety data supports using either in breastfeeding women. Metformin transfers at low levels; limited evidence suggests it is probably compatible with breastfeeding, as referenced in LactMed, though a direct conversation with your clinician is appropriate.

A responsible prescribing platform asks about pregnancy status and breastfeeding at intake and at every prescription renewal. Women should verify that Superpower's intake form asks these questions before they enroll.

Who This Platform May Suit and Who Should Look Elsewhere

The following is framed by life stage and medical context, not by marketing category.

Women Who May Find Value Here

Postmenopausal women with documented low testosterone and HSDD, who are not using hormonal contraception, have no history of hormone-sensitive cancer, and want a more accessible route to testosterone therapy than their current provider offers may find Superpower a reasonable starting point. They should still confirm that the prescribing clinician is familiar with The Menopause Society's position on testosterone and will monitor labs every 3 to 6 months.

Women with documented PCOS who want metformin and whose primary care access is limited may benefit from the platform's prescribing capacity, provided they are not trying to conceive actively, as metformin in that context should be managed alongside reproductive endocrinology.

Women Who Should Look Elsewhere

Women who are pregnant or actively trying to conceive should not use a general optimization platform for hormone or metabolic prescribing. ACOG and ASRM both emphasize coordinated, specialty-level care in these windows.

Breastfeeding women need a clinician who will check LactMed or an equivalent database for every agent prescribed. A platform without a documented lactation screening process is not the right fit.

Women in perimenopause, roughly ages 40 to 51, face the most complex hormonal picture of their lives: estrogen fluctuating unpredictably, testosterone declining, thyroid function sometimes shifting, and metabolic risk rising. A subscription platform built on static lab panels is a poor match for a physiology that changes month to month. The Menopause Society Certified Practitioner directory is a better starting point.

Women with a personal or family history of hormone-sensitive breast or ovarian cancer should have hormone prescribing managed by an oncologist-familiar gynecologist, not an optimization platform.

Superpower Complaints: What Users Have Reported

Consumer complaint data for Superpower is limited and skewed toward platforms where tech-savvy users complain, primarily Reddit threads and the BBB complaint portal. Documented complaint themes include:

• Difficulty canceling the monthly subscription after the first billing cycle
• Delays between lab draw and clinician review, sometimes exceeding two weeks
• Clinicians described as not familiar with women's hormonal health specifically
• Lab results flagged as abnormal with no follow-up protocol from the platform
• Prescription requests for female-specific concerns (cycle irregularity, HSDD) declined without referral

None of these complaints, taken individually, prove clinical negligence. Taken together, they sketch a platform optimized for a male-default optimization user, with patchy adaptation for women's needs.

Women with specific concerns such as PCOS, perimenopause, or postpartum thyroid changes are likely to hit the limits of this model faster than a generally healthy woman with no hormonal complexity.

The Evidence Gap Women Deserve to Know About

Women have been historically underrepresented in clinical research, a gap the NIH Sex as a Biological Variable policy has tried to address since 2016 but has not fully closed. Direct-to-consumer optimization platforms inherited this gap. Their protocols, drug choices, and dose targets are overwhelmingly derived from research conducted in men. When a platform prescribes testosterone or DHEA to women, it is extrapolating from male-derived data in most cases, not drawing on a rich female-specific evidence base.

This does not mean the prescribing is wrong. It means the uncertainty is higher than the platform's confident marketing implies. Women deserve to know they are in extrapolation territory so they can make genuinely informed decisions.

"The lack of sex-disaggregated outcomes data from direct-to-consumer health platforms is a specific patient-safety concern for women," says Elena Vasquez, MD, WomanRx's editorial board OB-GYN reviewer. "When a platform cannot tell me what percentage of its female members experienced cycle disruption, virilization, or thyroid suppression after starting prescribed protocols, I cannot endorse it as evidence-based care for my patients."

Practical Steps Before You Subscribe

1. Ask Superpower directly which state board licenses the clinician who will review your case.
2. Confirm that the dispensing pharmacy is NABP-verified.
3. Request the full list of drugs the platform can prescribe and ask specifically whether female-specific dosing protocols exist for each.
4. Ask whether the intake form screens for pregnancy, lactation, and fertility intentions before every prescription, not just at initial sign-up.
5. Get your follow-up lab monitoring schedule in writing before your first prescription is filled.
6. If you are in perimenopause, postpartum, or actively managing PCOS, ask whether any clinician on the platform holds a NAMS certification or equivalent women's-health specialty credential.

If Superpower cannot answer these questions promptly and specifically, that is your signal to seek care from a platform or clinician whose women's-health infrastructure is demonstrably stronger.